Update shared on 27 Nov 2025
Analysts have maintained their price target for ADMA Biologics at $27.25 per share, citing stable financial projections and consistent optimism regarding the company's growth prospects.
What's in the News
- From July 1, 2025 to September 30, 2025, ADMA Biologics repurchased 512,411 shares, completing a total buyback of 1,328,648 shares for $23.01 million as announced in May 2025 (Key Developments).
- ADMA Biologics raised its earnings guidance for fiscal year 2025 and now expects at least $510 million in total revenue, up from the previous estimate of more than $500 million (Key Developments).
- For fiscal year 2026, revenue expectations were also raised to at least $630 million, increased from prior guidance of $625 million or more (Key Developments).
- New guidance for 2029 was issued, with total annual revenue anticipated to reach $1.1 billion or more, reflecting expectations for strong earnings growth and operational progress (Key Developments).
Valuation Changes
- Consensus Analyst Price Target remains unchanged at $27.25 per share.
- Discount Rate has risen slightly from 7.02% to 7.05%.
- Revenue Growth expectations are consistent, holding at approximately 24.38%.
- Net Profit Margin shows no change, remaining steady at 41.14%.
- Future P/E ratio has fallen slightly from 20.90x to 20.66x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.